
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc has demonstrated a substantial increase in the projected enterprise value of its lead product, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy, raising it from $794 million to $2.30 billion, reflecting positive Phase III clinical trial results. The promising data indicates a significant 1.0 point improvement in the PUL 2.0 Mid-level Dimension, along with improvements in heart scarring among patients, underscoring the therapeutic potential of deramiocel. Furthermore, the anticipated revenue from the partnership with NSPharma enhances the financial outlook, suggesting a robust opportunity for significant net sales and overall growth in shareholder value.
Bears say
Capricor Therapeutics Inc faces significant clinical risks associated with its lead product, deramiocel, including potential challenges in safety, tolerability, and efficacy, which could hinder its progress through clinical trials and market approval. Additionally, the company may experience a slower-than-anticipated market penetration and revenue ramp, increasing the likelihood of needing to secure additional financing under unfavorable conditions, leading to potential shareholder dilution. Compounding these risks, recent data indicates a concerning decline in left ventricular ejection fraction (LVEF) among Duchenne muscular dystrophy patients, suggesting that the therapeutic market potential for deramiocel may not meet initial projections.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares